20 subjects with severe hepatic failure have been studied by means of all night polygraphic sleep recordings. Base night recordings have been made, as well as registrations after treatment with drugs that are known to improve the clinical conditions of these patients, especially concerning the psychic performances. Base night recordings show sleep disruption, with a large amount of wakefulness at the beginning of the registrations and during the night itself; sleep stages are strongly reduced, especially REM sleep. After L-dopa treatment, these negative patterns are furthermore enhanced and the percentage incidence of the REM stage is very low; nevertheless, this behaviour goes side by side with a light improvement in psychological performances. On the contrary, therapy with lactulose seems to improve the neuropsychiatric state and the sleep organization; as a matter of fact, wakefulness is lower in the night records after lactulose treatment, whilst the percentage incidence of sleep stages tends back toward normality; REM sleep has clearly risen.

Keywords:
Hepatic failure, Sleep, L-Dopa, Lactulose
This content is only available via PDF.
© 1978 S. Karger AG, Basel
1978
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.